By PAUL VON BÜNAU A staggering 85% of the human proteome has been deemed ‘undruggable’.…
Life Science and Healthcare
BANDIT: using diverse data to measure drug similarity and predict drug targets
By LUIS DREISBACH Similar small molecules tend to be similarly effective against disease, often sharing…
Taking out the trash: how protein degraders could help us fight disease
By PAUL VON BÜNAU Of the 75%+ of human proteins not currently targetable by drugs,…
Sci-fi or AI? What will a supercharged pharmaceutical industry look like?
By PAUL VON BÜNAU Fully digitised, AI-directed, in-silico drug discovery and development programs are not…
Correcting confounding biases in genome-wide association studies
By BENJAMIN HÄUSLER and RAPHAEL SCHYMCZYK Linkage disequilibrium score regression is already being put to…
Double strength: how can we better predict effective, as-yet untried, drug combinations?
By MONA SCHIRMER Some things just work better with two – but when it comes…
Drug development: how predictive algorithms could save big pharma billions
By PAUL VON BÜNAU Immense development costs and low success rates can make drug development…
AlphaFold: from accuracy to application?
By PAUL VON BÜNAU DeepMind AI’s impressive protein structure prediction accuracy hints at a huge…
Data Science for Pharma – A Short Case Study
By BENJAMIN HÄUSLER Open data in biomedicine is a gold mine that can strengthen innovation…
Structuring, connecting and discovering knowledge: Our biotech NLP platform helps to identify therapeutic targets from millions of scientific papers
By PAUL VON BÜNAU In biomedicine, much of the information generated is made publicly available…